• Gepotidacin for Gonorrhea: Phase 2 Efficacy, Resistance, and

  2026-04-29

  This article reviews the phase 2 trial evaluating gepotidacin, a novel bacterial type II topoisomerase inhibitor, for the treatment of uncomplicated urogenital gonorrhea. The study demonstrates high efficacy, addresses antibiotic resistance challenges, and provides a methodological foundation relevant for researchers studying bacterial protein synthesis inhibitors and antibacterial agents.

• Amikacin (BAY416651): Advanced Workflows in Resistance Resea

  2026-04-28

  Amikacin (BAY416651) stands apart as a robust bacterial protein synthesis inhibitor, uniquely suited for dissecting resistance in multidrug-resistant Enterobacter cloacae and Klebsiella pneumoniae. This guide delivers actionable workflows, troubleshooting strategies, and direct connections to landmark studies, maximizing the impact of APExBIO's research-grade antibiotic in experimental microbiology.

• 3-Aminobenzamide (PARP-IN-1): Crossroads of Vascular and Ant

  2026-04-28

  Discover the unique scientific potential of 3-Aminobenzamide (PARP-IN-1) as a bridge between vascular biology and antiviral research. This in-depth analysis spotlights advanced poly (ADP-ribose) polymerase inhibition and the latest mechanistic insights.

• Applied Uses of CA-074: Cathepsin B Inhibitor for Disease Mo

  2026-04-27

  CA-074, a highly selective cathepsin B inhibitor from APExBIO, unlocks precise modulation of protease-driven pathways in cancer, neurodegeneration, and immune research. This article distills experimental workflows, troubleshooting tactics, and protocol enhancements—bridging recent necroptosis findings with actionable lab strategies.

• Clarithromycin as a CYP3A Inhibitor: Applied Workflows & Tro

  2026-04-27

  Clarithromycin’s precision as a potent CYP3A inhibitor enables rigorous pharmacokinetic and drug-drug interaction research, particularly in statin and cardiovascular drug studies. This guide delivers stepwise workflows, advanced assay strategies, and expert troubleshooting for maximizing experimental reliability with APExBIO’s gold-standard compound.

• Tacalcitol Monohydrate: Applied Workflows in Dermatology & O

  2026-04-26

  Tacalcitol monohydrate, a synthetic analog of vitamin D3, unlocks precise control of keratinocyte biology and cancer cell modulation through robust NGF induction and VDR-mediated gene regulation. This guide distills protocol enhancements, experimental insights, and troubleshooting strategies, showing why APExBIO’s formulation is trusted for both advanced dermatological and oncology research.

• Rapamycin (Sirolimus) SKU A8167: Reliable mTOR Inhibition in

  2026-04-25

  This article offers a scenario-driven, evidence-based guide to using Rapamycin (Sirolimus) (SKU A8167) for robust mTOR pathway inhibition in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed data and practical laboratory insights, it demonstrates how this reagent from APExBIO delivers reproducibility, sensitivity, and clear interpretability for advanced biomedical research.

• Tropisetron Hydrochloride: Optimizing 5-HT3 Receptor Antagon

  2026-04-24

  Tropisetron Hydrochloride delivers precision modulation for serotonin 5-HT3 and α7-nicotinic receptors, enabling reproducible neuroscience and transporter assays. This article translates leading-edge assay design, troubleshooting strategies, and the latest insights from renal transporter research into tangible experimental workflows.

• Trelagliptin Succinate: Mechanistic Insights and Experimenta

  2026-04-24

  Explore the advanced molecular mechanisms and practical assay guidance for Trelagliptin succinate in diabetes mellitus research. This article uniquely decodes how SYR-472 succinate modulates insulin resistance and provides actionable, evidence-based protocols for translational studies.

• Phenytoin in Translational Research: Mechanisms, Models, and

  2026-04-23

  Explore how Phenytoin (5,5-diphenylimidazolidine-2,4-dione) advances sodium channel modulation research, with actionable protocol guidance and strategic insight for translational neuroscience. This article integrates mechanistic evidence, competitive landscape analysis, and practical workflow recommendations, positioning APExBIO's high-purity Phenytoin as a cornerstone for next-generation electrophysiology and neurological disease modeling.

• Tobramycin: Optimizing Gram-Negative Research Workflows

  2026-04-23

  Tobramycin’s water solubility and verified purity empower reproducible Gram-negative bacterial research, streamlining both MIC assays and resistance studies. This article distills advanced workflows, troubleshooting strategies, and actionable protocol parameters to help microbiology researchers maximize the reliability and impact of APExBIO’s Tobramycin.

• 2-(4,5,6,7-tetrabromo...)acetic acid: A Next-Gen Small Molec

  2026-04-22

  Leverage the CK2 and ERK8 inhibitor (2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid) for precise modulation of kinase-driven signaling and advanced studies of protein phase separation. This high-purity, DMSO-soluble small molecule from APExBIO enables robust biochemical workflows, with built-in troubleshooting guidance for reproducibility.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit: Workflow & B

  2026-04-22

  The HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit streamlines fluorescent RNA probe synthesis for sensitive detection in in situ and Northern blot hybridization. This guide dissects protocol optimization, advanced workflow enhancements, and troubleshooting strategies, bridging bench innovations with robust, reproducible research.

• Repurposing Natural Compounds: In Silico Inhibition of SARS-

  2026-04-21

  Eskandari et al. (2022) systematically screened vitamins and natural compounds for their ability to inhibit SARS-CoV-2 main protease (3CLpro) and spike protein receptor-binding domain (RBD) via molecular docking and dynamics. Their findings highlight accessible molecules with stable binding at key viral interfaces, informing both antiviral discovery and mechanistic studies in COVID-19 research.

• Mechanistic cDNA Synthesis: Strategic Insights for Translati

  2026-04-21

  This article explores how mechanistic advances in reverse transcription—epitomized by the HyperScript™ First-Strand cDNA Synthesis Kit—unlock new frontiers for translational researchers. By integrating findings from recent fruit abscission transcriptomics and leveraging engineered enzyme performance, we provide a roadmap for overcoming RNA complexity, ensuring robust gene expression analysis, and advancing the fidelity of translational workflows.

407 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page